Bullish
Pfizer's TUKYSA regimen approved for front-line HER2+ breast cancer maintenance
Pfizer's TUKYSA regimen, in combination with trastuzumab and pertuzumab, has been approved by the FDA as a front-line maintenance treatment for HER2-positive metastatic breast cancer. This approval offers a new chemotherapy-free maintenance option, potentially improving progression-free survival for patients.
Key points
- FDA approval of TUKYSA regimen for front-line HER2+ breast cancer maintenance.
- Pfizer to present infectious disease advancements at IDWeek 2026.
- Scotiabank raises Pfizer's price target to $33 from $30.
Sources
- Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast CancerBusiness Wire · October 7, 2026
- Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026Business Wire · October 14, 2026
- Pfizer price target raised to $33 from $30 at ScotiabankTheFly · October 8, 2026
AI-generated from public news sources. Not financial advice.
